- Conditions
- Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 74
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Interventions
- 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT)
- Drug · Procedure
- Lead sponsor
- Sue O'Dorisio
- Other
- Eligibility
- 1 Year to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Not listed
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- 131 I-Metaiodobenzylguanidine (131 I-MIBG)
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
- Interventions
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Diagnostic Test · Drug · Other
- Lead sponsor
- Taproot Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Idaho Falls, Idaho • Laredo, Texas
- Conditions
- Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
- Interventions
- SGI-110 (guadecitabine)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Phenoxybenzamine, Doxazosin
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neuroblastoma, Childhood Metastatic Pheochromocytoma
- Interventions
- 131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
- Drug
- Lead sponsor
- John Maris
- Other
- Eligibility
- 1 Year and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Ultratrace® Iobenguane I131
- Radiation
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Iowa City, Iowa + 7 more
- Conditions
- Neuroblastoma, Pheochromocytoma
- Interventions
- 18F-DA
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Interventions
- I-131 MIBG, Vorinostat
- Radiation · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Months and older
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Paraganglioma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Talazoparib, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
- Interventions
- Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib
- Procedure · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pheochromocytoma
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1988 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Familial Renal Cancer (FRC), Clear Cell Renal Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1990
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Interventions
- octreotide acetate, yttrium Y 90 resin microspheres
- Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more
- Conditions
- Medullary Thyroid Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 4 Months and older
- Enrollment
- 259 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- isolated perfusion, melphalan
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pheochromocytoma
- Interventions
- [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
- Interventions
- 177Lu-DOTATOC
- Drug
- Lead sponsor
- Excel Diagnostics and Nuclear Oncology Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
- Interventions
- Behavioral nudge
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
- Interventions
- Fostamatinib disodium
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland